The cohort analysis of the KEYNOTE-059 study indicated that ORR was comparatively higher in the PD-L1 CPS ≥ 1 group than in the CPS < 1 group (15.5% vs. 6.4%) in pembrolizumab-treated patients with previously treated gastric cancer [24]. The gene discussed is CD274; the disease is gastric cancer.